Sector News

Tevogen to go public in $1.2bn SPAC deal

July 2, 2023
Life sciences

There could soon be a TVGN ticker on the New York Stock Exchange (NYSE), after Tevogen Bio revealed plans of a billion-dollar deal to combine with special purpose acquisition company (SPAC) Semper Paratus Acquisition Corporation.

The New Jersey, US-based biotech company expects the value of the merger to be approximately $1.2bn and the combined company will trade under the name Tevogen Holdings. The transaction is pegged to be completed in the fourth quarter of 2023.

Tevogen Bio currently has a pipeline investigating T cell therapy. Its proprietary technology platform – ExacTcell – uses CD8+ cytotoxic T lymphocytes (CTLs) and uses the body’s native T cell receptor pool to provide enhanced safety.

In January 2023, the company reported positive data from its lead candidate TVGN 489 for the treatment of Covid-19 in high-risk patients. In the statement announcing public listing intention, Tevogen Bio said it will target therapies for non-viral-induced common cancers and multiple sclerosis upon completion of the transaction.

The transaction will also help the company pursue several late-stage trials and expand its manufacturing capacity.

The biotech industry has been in a lull of initial public offerings, and 2023 has seen fundraising difficulties amidst rising inflation.

“Tevogen Bio’s goal is to provide access to the vast and unprecedented potential of personalised immunotherapies for large patient populations impacted by common cancers and viral infections,” Tevogen Bio’s founder and CEO, Dr Ryan Saadi said.

“Tevogen Bio’s rapid growth from concept to a fully operational biotech company in less than 24 months is the result of ambitious goals and well-executed strategies by its highly motivated and skilled team of experts,” said Semper Paratus ‘s CEO Suren Ajjarapu.

By Robert Barrie

Source: pharmaceutical-technology.com

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach